

Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2025

We achieved a pivotal milestone during the second quarter, as strong clinical results clearly confirmed the diagnostic value of JUNO-Checked.

JANUARY 1st - JUNE 30st 2025

SIGNIFICANT EVENTS DURING THE QUARTER

| 02-04-2025 | Spermosens reports positive second interim results from clinical study |
|------------|--|
| 07-05-2025 | Spermosens AB INTERIM REPORT JANUARY – MARCH 2025 |
| 15-05-2025 | NOTICE OF ANNUAL GENERAL MEETING 2025 IN SPERMOSENS AB |
| 26-05-2025 | Spermosens publishes annual report for the financial year 2024 |
| 02-06-2025 | The subscription price for warrants of series TO 5 has been determined – the exercise period begins today |
| 05-06-2025 | The capital raise and issue announced in March 2025 is approved by Inspectorate of Strategic Products |
| 11-06-2025 | Spermosens concludes clinical study with statistically significant results supporting the diagnostic value of JUNO-Checked |
| 13-06-2025 | Chairman and CEO of Spermosens exercise TO5 warrants |
| 16-06-2025 | Spermosens AB Announces Results from Annual General Meeting on 16 June 2025 |
| 17-06-2025 | Spermosens announces outcome of exercise of warrants series TO 5 |

FINANCIAL INFORMATION

| | 2025 | 2024 | 2025 | 2024 | 2024 | Rolling |
|----------------------------------|-----------|---------|-----------|------------|-----------|-----------|
| Amounts in SEK thousand | Q2 | Q2 | Q1-Q2 | Q1-Q2 | Full-Year | 12 mth |
| Net sales | - | _ | _ | _ | _ | 1 _ |
| Operating profit/loss | -2 662 | -2 055 | -4 725 | -4 659 | -9 163 | -9 229 |
| - Whereof activated work for own | | | | | | |
| account | 93 | 1 264 | 488 | 2 925 | 2 387 | -50 |
| Cash and cash equivalents | 11 817 | 12 862 | 11 817 | 12 862 | 4 492 | 11 817 |
| Total Cash flow | | | 11 158 | 6 171 | -3 833 | 1 154 |
| Equity end of period | 36 879 | 24 132 | 36 879 | 24 132 | 12 692 | 36 879 |
| Balance sheet total | 38 614 | 27 302 | 38 614 | 27 302 | 26 105 | 38 614 |
| Equity/assets ratio,% | 96 | 88 | 96 | 88 | 49 | 96 |
| Liquidity ratio,% | 749 | 125 | 749 | 125 | 43 | 749 |
| | 3 084 312 | 283 607 | 3 084 312 | 283 607 | 3 084 312 | 1 696 939 |
| No. of shares | 991 | 120 | 991 | 120 | 991 | 755 |
| Weighted average number of | | | | | | |
| shares, adjusted for | 1 893 822 | 140 852 | 1 696 939 | | 187 569 | 1 074 427 |
| dilution effect (thousands) | 350 | 536 | 755 | 90 475 530 | 007 | 067 |
| Earnings per share, SEK | 0,00 | -0,02 | 0,00 | -0,06 | 0,04 | -0,01 |
| Number of employees at end of | | | | | | |
| period | 4 | 6 | 4 | 6 | 3 | 4 |

CEO's COMMENTS

We achieved a pivotal milestone during the second quarter, as strong clinical results clearly confirmed the diagnostic value of JUNO-*Checked*. This outcome represents a major validation of our technology and significantly strengthens our ability to move the solution forward together with future partners.

The clinical study, conducted at the Reproductive Medicine Center in Malmö, showed a clear and statistically significant correlation between the JUNO Score — which measures sperm binding to the JUNO receptor of the egg — and fertilization rates in IVF. Notably, 22% of the men had a low JUNO Score despite normal sperm parameters. This underscores the limitations of conventional semen analysis and highlights the unique insights JUNO-Checked provides at a critical stage of fertilization.

The results show why JUNO-*Checked* could become a game changer in the infertility market. It has the potential to improve IVF outcomes, support better selection of sperm donors, and even help identify periods of peak fertility in men. With much infertility still unexplained and current methods limited, JUNO-*Checked* provides information that was previously unavailable — insights that can eventually bring real value to patients, clinicians and sperm banks.


The significance of this milestone is already reflected in our business development. The clinical validation has increased the interest from companies established Assisted Reproductive Technology (ART) market, strengthening our confidence as we advance our licensing and partnership strategy.

The TO5 warrants were fully exercised during the quarter. Together with strategic investments in the first quarter, we have the financial resources needed to execute our plans. This allows us to focus on developing the third-generation JUNO-*Checked* system, ensuring higher throughput, faster analysis, and smooth integration into routine laboratory practice.

I am fortunate to work alongside highly skilled and dedicated people whose expertise and stamina have been instrumental in reaching this milestone. My sincere thanks go to the Reproductive Medicine Center in Malmö, whose collaboration made this achievement possible.

I also appreciate the commitment of our development partners and the confidence of our investors — all of which enable us to continue progressing toward a solution that may help many affected by infertility, while creating value for shareholders.

With JUNO-Checked now clinically validated, increasing interest from potential partners, and the resources to move forward, I feel confident in our chance to succeed. Our focus remains firmly on advancing JUNO-Checked toward the market.



love broad

Tore Duvold, CEO of Spermosens AB

20 August 2025